The Oncology Institute, Inc. (TOI)
| Market Cap | 340.01M |
| Revenue (ttm) | 502.73M |
| Net Income (ttm) | -50.31M |
| Shares Out | 98.84M |
| EPS (ttm) | -0.54 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 675,608 |
| Open | 3.300 |
| Previous Close | 3.330 |
| Day's Range | 3.300 - 3.445 |
| 52-Week Range | 2.015 - 4.880 |
| Beta | 0.20 |
| Analysts | Strong Buy |
| Price Target | 6.67 (+94.75%) |
| Earnings Date | May 7, 2026 |
About TOI
The Oncology Institute, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-house infusion, in-house specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services, as well as educational seminars, support groups, counseling services, and 24/7 patient assistance and support services. It also manages clinical trials and palliativ... [Read more]
Financial Performance
In 2025, The Oncology Institute's revenue was $502.73 million, an increase of 27.79% compared to the previous year's $393.41 million. Losses were -$50.31 million, -5.09% less than in 2024.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for TOI stock is "Strong Buy." The 12-month stock price target is $6.67, which is an increase of 94.75% from the latest price.
News
The Oncology Institute Announces First Quarter 2026 Earnings Release Date and Conference Call
CERRITOS, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI) a pioneer in value-based community oncology care, today announced that the company will release ...
The Oncology Institute Transcript: 25th Annual Needham Virtual Healthcare Conference
A value-based oncology provider is expanding rapidly through delegated contracts, especially in Florida, and expects significant growth in capitated revenue and profitability through 2028. The dispensary segment has become the largest revenue driver, and AI initiatives are set to enhance efficiency and margins.
The Oncology Institute Earnings Call Transcript: Q4 2025
Achieved first profitable quarter on adjusted EBITDA in Q4 2025, with revenue up 28% year-over-year and strong growth in pharmacy and capitated care. 2026 guidance projects continued revenue and margin expansion, with positive free cash flow expected by year-end.
The Oncology Institute Reports Fourth Quarter and Full Year 2025 Financial Results and Guidance for 2026
CERRITOS, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States,...
U.S. Neurology Associates Partners with M33 Growth to Transform Neurological Care
DALLAS and BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- M33 Growth, a Boston-based venture and growth-stage investment firm, today announced its partnership with U.S. Neurology Associates (“USNA” or the ...
The Oncology Institute Announces Leadership Promotions
Rakesh Panda appointed Chief Information Officer Nolan Mariano appointed Chief People Officer CERRITOS, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) announced t...
The Oncology Institute Announces Resignation of Board Member Gabe Ling
CERRITOS, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that Gabe L...
The Oncology Institute Earnings Call Transcript: Q3 2025
Q3 2025 saw 36.7% revenue growth, record Pharmacy results, and improved adjusted EBITDA, with the first profitable month in September. Guidance for 2025 was raised, and operational momentum is strong, supported by new contracts, AI initiatives, and expanding payer relationships.
Ascertain and The Oncology Institute Co-Develop ‘Touchless' AI Automation for Oncology Administration
Partnership deployed touchless prior authorization system in eight weeks, achieving 95% reduction in authorization workload Partnership deployed touchless prior authorization system in eight weeks, ac...
The Oncology Institute Announces Third Quarter 2025 Earnings Release Date and Conference Call
CERRITOS, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI), a pioneer in value-based community oncology care, today announced that the company will release...
The Oncology Institute Transcript: Noble Capital Markets Emerging Growth Virtual Investor Conference
Oncology care costs are rising unsustainably, but a value-based model with employed clinicians and proprietary care pathways is delivering significant cost savings, high patient satisfaction, and robust financial growth. Expansion focuses on existing high-utilization markets, with profitability projected in Q4.
The Oncology Institute Launches Lung Cancer Center of Excellence in Florida Led by International Oncology Expert Dr. Edgardo Santos
CERRITOS, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute of Hope and Innovation (NASDAQ: TOI), a leading value-based oncology practice, today announced the launch of its Lung Cancer...
The Oncology Institute Earnings Call Transcript: Q2 2025
Q2 2025 saw over 20% revenue growth, strong pharmacy expansion, and improved margins, with new value-based contracts and a path to positive adjusted EBITDA by Q4. Leadership changes and AI initiatives support further efficiencies and growth.
The Oncology Institute Reports Second Quarter 2025 Financial Results and Reaffirms Full Year 2025 Guidance
CERRITOS, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, ...
The Oncology Institute Announces Changes to Board of Directors
Richard Barasch to Retire; Anne McGeorge Brings Extensive Financial Experience to Role as New Chairman Richard Barasch to Retire; Anne McGeorge Brings Extensive Financial Experience to Role as New Cha...
The Oncology Institute Names Kristin England as Chief Administrative Officer
CERRITOS, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI”), one of the largest value-based oncology groups in the United States, announced today that Kristi...
The Oncology Institute and SilverSummit Healthplan Partner to Provide Oncology Care to Over 80,000 Medicaid Members in Nevada
CERRITOS, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI”), one of the largest value-based oncology groups in the United States, announced today that effect...
The Oncology Institute set to join the Russell 2000® and Russell 3000® Indexes
CERRITOS, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI”), one of the largest value-based oncology groups in the United States, today announced that it wil...
The Oncology Institute Earnings Call Transcript: Q1 2025
Q1 2025 saw 10% revenue growth and a 44% increase in gross profit, driven by strong dispensary performance and new capitated contracts. Guidance for 2025 is reaffirmed, with positive adjusted EBITDA and cash flow targeted for Q4. Balance sheet strengthened through debt reduction and capital raise.
The Oncology Institute Welcomes Dr. Jeff Langsam as Chief Clinical Officer
CERRITOS, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI”), one of the largest value-based oncology groups in the United States, announced today that Dr. Jef...
The Oncology Institute to Participate at the B. Riley Securities 25th Annual Institutional Investor Conference
CERRITOS, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI”), one of the largest value-based oncology groups in the United States, today announced that Dr. Dan...
The Oncology Institute Announces First Quarter 2025 Earnings Release Date and Conference Call
CERRITOS, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI) one of the largest value-based oncology groups in the United States, today announced that the co...
TOI Launches Florida Oncology Network, a Fully Delegated Cancer Care Network, and Announces Four Additional Value-based Contracts in Q1
CERRITOS, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States,...
The Oncology Institute Earnings Call Transcript: Q4 2024
Revenue grew 21% in 2024, driven by value-based contracts and pharmacy expansion, while cost controls and capital actions improved cash flow and reduced debt. 2025 guidance targets 17–22% revenue growth, margin expansion, and profitability by year-end, with Florida as a key growth market.
The Oncology Institute Reports Fourth Quarter and Full Year 2024 Financial Results and Guidance for 2025
CERRITOS, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States,...